We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-3.83%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$928M
AUM Growth
-$21.2M
Cap. Flow
+$44.5M
Cap. Flow %
4.8%
Top 10 Hldgs %
34.27%
Holding
87
New
4
Increased
25
Reduced
17
Closed
2

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$9.79M
2
CRL icon
Charles River Laboratories
CRL
+$9.03M
3
ISRG icon
Intuitive Surgical
ISRG
+$7.34M
4
PRCT icon
Procept Biorobotics
PRCT
+$7.3M
5
MDT icon
Medtronic
MDT
+$6.95M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$9.98M
2
ZBH icon
Zimmer Biomet
ZBH
+$9.91M
3
ELV icon
Elevance Health
ELV
+$8.16M
4
UNH icon
UnitedHealth
UNH
+$6.89M
5
MOH icon
Molina Healthcare
MOH
+$6.54M

Sector Composition

Rank Sector Weight
1 Healthcare 99.51%
2 Industrials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DHR icon
26
Danaher
DHR
$147B
$14.9M 1.61%
67,680
– –
BIIB icon
27
Biogen
BIIB
$30.6B
$14.5M 1.57%
56,500
-8,000
-12% -$2.14M
AXNX
28
DELISTED
Axonics, Inc. Common Stock
AXNX
$12.9M 1.39%
230,000
– –
NTRA icon
29
Natera
NTRA
$45.9B
$11.8M 1.27%
266,769
+66,769
+33% +$3.41M
LNTH icon
30
Lantheus
LNTH
$6.59B
$11.7M 1.26%
168,000
+68,000
+68% +$4.97M
IMGN
31
DELISTED
Immunogen Inc
IMGN
$11.1M 1.2%
700,000
-50,000
-7% -$832K
EXAS
32
DELISTED
Exact Sciences
EXAS
$10.9M 1.18%
160,000
-15,000
-9% -$1.27M
PRVA icon
33
Privia Health
PRVA
$2.86B
$10.6M 1.14%
460,000
– –
ALKS icon
34
Alkermes
ALKS
$8.29B
$10.4M 1.12%
370,000
+20,000
+6% +$586K
DVAX
35
DELISTED
Dynavax Technologies
DVAX
$10.3M 1.11%
700,000
– –
IQV icon
36
IQVIA
IQV
$39.8B
$9.25M 1%
47,000
– –
CRL icon
37
Charles River Laboratories
CRL
$13.2B
$8.62M 0.93%
+44,000
New +$9.03M
ALHC icon
38
Alignment Healthcare
ALHC
$2.86B
$8.33M 0.9%
1,200,000
+200,000
+20% +$1.21M
APLS
39
DELISTED
Apellis Pharmaceuticals
APLS
$8.18M 0.88%
215,000
+25,000
+13% +$1.1M
ALNY icon
40
Alnylam Pharmaceuticals
ALNY
$29B
$7.97M 0.86%
45,000
– –
MRTX
41
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$7.62M 0.82%
175,000
+35,000
+25% +$1.25M
ZBH icon
42
Zimmer Biomet
ZBH
$18.7B
$6.73M 0.73%
60,000
-78,000
-57% -$9.91M
IMVT icon
43
Immunovant
IMVT
$8.24B
$6.38M 0.69%
166,061
+66,061
+66% +$1.49M
NBIX icon
44
Neurocrine Biosciences
NBIX
$16.8B
$6.14M 0.66%
54,566
+14,566
+36% +$1.53M
KRTX
45
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$5.92M 0.64%
35,000
– –
CYTK icon
46
Cytokinetics
CYTK
$10.5B
$5.89M 0.64%
200,000
– –
BNTX icon
47
BioNTech
BNTX
$23.3B
$5.76M 0.62%
53,000
-17,000
-24% -$1.88M
GKOS icon
48
Glaukos
GKOS
$10.7B
$5.49M 0.59%
73,000
-22,000
-23% -$1.64M
ITCI
49
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.95M 0.53%
95,000
– –
VEEV icon
50
Veeva Systems
VEEV
$38.1B
$4.68M 0.5%
23,000
-12,000
-34% -$2.42M
1
2
3 4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2023 Portfolio in Review

As of Q3 2023, Rhenman & Partners Asset Management held 87 positions worth $928M, down 2.2% from $949M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rhenman & Partners Asset Management deployed $44.5M of net new capital in Q3 2023, opening 4 new positions and adding to 25 existing holdings. Its largest new stake was Charles River Laboratories: 44,000 shares worth $8.62M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Cigna, an estimated $9.98M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2023 buy was Charles River Laboratories: 44,000 shares worth $8.62M.
  • Rhenman & Partners Asset Management added most to Eli Lilly in Q3 2023, an estimated $9.79M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2023 reduction was Cigna, cutting an estimated $9.98M.
  • Rhenman & Partners Asset Management fully exited Molina Healthcare in Q3 2023, selling an estimated $6.54M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $928M portfolio in Q3 2023.
  • Rhenman & Partners Asset Management opened 4 new positions and closed 2 in Q3 2023.
  • Rhenman & Partners Asset Management's portfolio value fell 2.2% quarter-over-quarter to $928M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2023, filed 9 Nov 2023.